SOST and chronic kidney disease: However, with the progression of CKD, Wnt inhibitors such as sclerostin and Dickkopf WNT signaling pathway inhibitor 1 have been shown to be increased [29,30,31,32], leading to the inhibition of canonical Wnt/β-catenin signaling and decreased bone formation.